Truist Financial Reaffirms Buy Rating for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY)‘s stock had its “buy” rating reissued by Truist Financial in a research note issued to investors on Monday,MarketScreener reports.

Several other equities analysts have also weighed in on LLY. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Barclays began coverage on shares of Eli Lilly and Company in a research note on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price target on the stock. Daiwa Securities Group upped their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,229.33.

Eli Lilly and Company Stock Down 0.2%

Shares of NYSE:LLY traded down $2.47 during trading hours on Monday, hitting $1,039.68. The company’s stock had a trading volume of 423,379 shares, compared to its average volume of 3,305,907. The firm’s fifty day moving average price is $1,054.49 and its 200 day moving average price is $923.72. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a market capitalization of $980.79 billion, a price-to-earnings ratio of 45.61, a P/E/G ratio of 1.23 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Exencial Wealth Advisors LLC increased its position in Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after buying an additional 11,396 shares in the last quarter. Rede Wealth LLC purchased a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $487,000. Central Pacific Bank Trust Division raised its stake in Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after purchasing an additional 1,843 shares during the period. Cidel Asset Management Inc. boosted its holdings in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after acquiring an additional 5,591 shares during the last quarter. Finally, Oak Family Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at about $1,979,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rival trial setback reinforces Lilly’s lead in obesity drugs — Novo’s CagriSema failed to match tirzepatide in an 84‑week head‑to‑head, bolstering expectations that Lilly’s Zepbound/Mounjaro will maintain market share and pricing power. Read More.
• Positive Sentiment: Zepbound multi‑dose pen approval improves patient convenience and retention — FDA OK for a multi‑dose weekly pen reduces switching friction and could support longer treatment duration and recurring revenue. Read More.
• Positive Sentiment: Analyst and pipeline support — Wall Street firms (e.g., Goldman) are keeping bullish views and high price targets, and Lilly reported additional positive trial/licensing updates that underscore long‑term growth beyond GLP‑1s. Read More.
• Neutral Sentiment: Product strategy to boost retention — Lilly’s multi‑dose pen and other convenience moves aim to reduce refill churn; execution matters but the strategic intent is positive for long‑term demand. Read More.
• Negative Sentiment: Novo’s planned U.S. list‑price cuts (up to ~50%) for Ozempic/Wegovy create pricing tailwinds for patients but pose clear competitive pricing pressure across the GLP‑1 market that could compress Lilly’s realized prices and near‑term revenue. Read More.
• Negative Sentiment: Market reaction and investor worry over revenue impact — After Novo’s price‑cut plans surfaced, Lilly shares showed short‑term weakness as investors price in potential margin/market‑share shifts despite the trial win. Read More.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.